Skip to main content
Premium Trial:

Request an Annual Quote

GATC to Provide Support for MolecularHealth's New Lab

NEW YORK (GenomeWeb News) – MolecularHealth today announced an agreement under which GATC Biotech will provide its laboratory information management system in MolecularHealth's new clinical laboratory.

GATC also will provide protocols, support, and training to MolecularHealth's staff. The deal, MolecularHealth said, will complement its next-generation sequencing offerings and its TreatmentMap oncology treatment decision support platform, which is anticipated to launch in the current quarter.

"GATC Biotech has decades of experience in sequencing technology and services, and a standardized, validated, automated process," MolecularHealth CEO Lloyd Everson said in a statement. "Their proven expertise will be invaluable to our team, as we work to provide personalized, actionable information to cancer patients and their medical teams."

Financial and other terms of the deal were not disclosed.

MolecularHealth separately announced the opening this week of its US headquarters and clinical lab in The Woodlands, Texas. The office and lab occupies about 7,000-square-feet of space, and the company expects to hire approximately 40 people in 2014, it said. The lab will be equipped with Illumina sequencing equipment and offer two tests, a gene panel of more than 500 known cancer genes, and whole exome sequencing of the tumor genome.

The Scan

Time to Act

A new report urges the UK to consider regulations to protect against the misuse of genomic technologies, according to the Guardian.

Fulgent Seeking Defamation Suit

Fulgent Genetics says it plans to sue Los Angeles County Sheriff Alex Villanueva for defamation, the Los Angeles Times reports.

Speeding Gene-Edited Crops

Reuters reports that China's new trial rules will make it easier to grow gene-edited crops there.

Nucleic Acids Research Papers on Viral Recombination, Pan-Cancer Mutations, SARS-CoV-2 Variability

In Nucleic Acids Research this week: updated pipeline to detect viral recombination, mutational patterns in tumor samples, and more.